SEB Asset Management AB Acquires Shares of 76,500 Progyny, Inc. $PGNY

SEB Asset Management AB bought a new stake in Progyny, Inc. (NASDAQ:PGNY) during the 1st quarter, HoldingsChannel reports. The fund bought 76,500 shares of the company’s stock, valued at approximately $1,299,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Caitong International Asset Management Co. Ltd purchased a new stake in Progyny in the 4th quarter valued at about $25,000. Hantz Financial Services Inc. raised its position in shares of Progyny by 79.4% in the 4th quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock worth $43,000 after acquiring an additional 742 shares in the last quarter. Canada Pension Plan Investment Board purchased a new stake in shares of Progyny during the second quarter valued at about $77,000. Quarry LP lifted its position in Progyny by 2,004.1% during the third quarter. Quarry LP now owns 3,598 shares of the company’s stock valued at $77,000 after acquiring an additional 3,427 shares during the last quarter. Finally, New Age Alpha Advisors LLC purchased a new stake in shares of Progyny during the 4th quarter valued at $94,000. 94.93% of the stock is owned by institutional investors.

Insider Activity at Progyny

In other Progyny news, Director Kevin K. Gordon sold 5,500 shares of Progyny stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $24.99, for a total value of $137,445.00. Following the completion of the transaction, the director directly owned 9,318 shares of the company’s stock, valued at $232,856.82. The trade was a 37.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Mark S. Livingston sold 8,275 shares of Progyny stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $25.50, for a total transaction of $211,012.50. Following the completion of the transaction, the chief financial officer owned 79,063 shares of the company’s stock, valued at $2,016,106.50. This trade represents a 9.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 36,916 shares of company stock valued at $939,875 over the last quarter. 9.90% of the stock is owned by insiders.

Progyny Trading Down 2.1%

PGNY stock opened at $30.70 on Friday. The company has a market cap of $2.40 billion, a price-to-earnings ratio of 39.87, a PEG ratio of 2.49 and a beta of 1.01. The firm has a 50-day moving average of $27.75 and a two-hundred day moving average of $23.05. Progyny, Inc. has a 12 month low of $16.10 and a 12 month high of $33.06.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.50 EPS for the quarter, topping the consensus estimate of $0.26 by $0.24. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The business had revenue of $328.50 million for the quarter, compared to analyst estimates of $326.46 million. During the same quarter in the previous year, the firm earned $0.17 EPS. The company’s quarterly revenue was down 26.4% compared to the same quarter last year. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. As a group, equities analysts forecast that Progyny, Inc. will post 1.19 earnings per share for the current year.

Progyny announced that its Board of Directors has authorized a share buyback plan on Tuesday, May 26th that permits the company to repurchase $200.00 million in outstanding shares. This repurchase authorization permits the company to repurchase up to 10.3% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its shares are undervalued.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Weiss Ratings raised shares of Progyny from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, June 26th. Canaccord Genuity Group boosted their price target on Progyny from $30.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday. Bank of America upped their price target on Progyny from $29.00 to $31.00 and gave the stock a “buy” rating in a report on Tuesday, June 2nd. Truist Financial increased their price objective on shares of Progyny from $30.00 to $33.00 and gave the company a “buy” rating in a report on Monday, June 22nd. Finally, Wall Street Zen upgraded shares of Progyny from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, Progyny presently has an average rating of “Moderate Buy” and a consensus target price of $31.83.

Progyny Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.